Bile Duct Cancer Treatment–for health professionals (PDQ®)

SECTIONS

Changes to This Summary (12/09/2015)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Localized Bile Duct Cancer

Added text about a phase II Southwest Oncology Group (SWOG) cooperative trial (S0809) that evaluated adjuvant capecitabine and gemcitabine followed by chemoradiation for patients with resected extrahepatic cholangiocarcinoma and gallbladder cancer. Also added statistical data to support findings of the trial (cited Ben-Josef et al. as reference 5 and level of evidence 3iiiDiv).

This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section

Unresectable, Recurrent, or Metastatic Bile Duct Cancer

Next section >

About This PDQ Summary